Department of Cardiac Surgery (M.T.B., M.N., J.E.M.), Harvard Medical School, MA.
Department of Cardiology (M.T.B., L.A.S., A.E.R., J.W.N.), Harvard Medical School, MA.
Circ Genom Precis Med. 2020 Aug;13(4):e002836. doi: 10.1161/CIRCGEN.119.002836. Epub 2020 Jun 30.
De novo genic and copy number variants are enriched in patients with congenital heart disease, particularly those with extra-cardiac anomalies. The impact of de novo damaging variants on outcomes following cardiac repair is unknown.
We studied 2517 patients with congenital heart disease who had undergone whole-exome sequencing as part of the CHD GENES study (Congenital Heart Disease Genetic Network).
Two hundred ninety-four patients (11.7%) had clinically significant de novo variants. Patients with de novo damaging variants were 2.4 times more likely to have extra-cardiac anomalies (=5.63×10). In 1268 patients (50.4%) who had surgical data available and underwent open-heart surgery exclusive of heart transplantation as their first operation, we analyzed transplant-free survival following the first operation. Median follow-up was 2.65 years. De novo variants were associated with worse transplant-free survival (hazard ratio, 3.51; =5.33×10) and longer times to final extubation (hazard ratio, 0.74; =0.005). As de novo variants had a significant interaction with extra-cardiac anomalies for transplant-free survival (=0.003), de novo variants conveyed no additional risk for transplant-free survival for patients with these anomalies (adjusted hazard ratio, 1.96; =0.06). By contrast, de novo variants in patients without extra-cardiac anomalies were associated with worse transplant-free survival during follow-up (hazard ratio, 11.21; =1.61×10) than that of patients with no de novo variants. Using agnostic machine-learning algorithms, we identified de novo copy number variants at 15q25.2 and 15q11.2 as being associated with worse transplant-free survival and 15q25.2, 22q11.21, and 3p25.2 as being associated with prolonged time to final extubation.
In patients with congenital heart disease undergoing open-heart surgery, de novo variants were associated with worse transplant-free survival and longer times on the ventilator. De novo variants were most strongly associated with adverse outcomes among patients without extra-cardiac anomalies, suggesting a benefit for preoperative genetic testing even when genetic abnormalities are not suspected during routine clinical practice. Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01196182.
新生基因和拷贝数变异在先天性心脏病患者中更为常见,尤其是那些伴有心脏外异常的患者。新生致病变异对心脏修复后结局的影响尚不清楚。
我们研究了 2517 名接受过全外显子组测序的先天性心脏病患者,这些患者是 CHD GENES 研究(先天性心脏病遗传网络)的一部分。
294 名患者(11.7%)存在有临床意义的新生致病变异。有新生致病变异的患者发生心脏外异常的可能性是无变异患者的 2.4 倍(比值比=5.63×10)。在 1268 名接受过手术数据且仅接受心脏直视手术(不包括心脏移植)作为首次手术的患者中,我们分析了首次手术后的无移植生存情况。中位随访时间为 2.65 年。新生致病变异与较差的无移植生存(风险比,3.51;=5.33×10)和最终拔管时间延长相关(风险比,0.74;=0.005)。由于新生致病变异对无移植生存有显著的与心脏外异常的交互作用(=0.003),因此对于伴有这些异常的患者,新生致病变异对无移植生存无额外风险(校正风险比,1.96;=0.06)。相比之下,在无心脏外异常的患者中,新生致病变异与随访期间较差的无移植生存相关(风险比,11.21;=1.61×10),而无新生致病变异的患者则无此相关性。使用非特定的机器学习算法,我们发现 15q25.2 和 15q11.2 的新生拷贝数变异与较差的无移植生存相关,而 15q25.2、22q11.21 和 3p25.2 则与拔管时间延长相关。
在接受心脏直视手术的先天性心脏病患者中,新生变异与无移植生存较差和呼吸机使用时间延长相关。在无心脏外异常的患者中,新生致病变异与不良结局的相关性最强,这表明即使在常规临床实践中未怀疑存在遗传异常,术前进行基因检测也可能有益。